R D Christensen1, R H Nussenzveig2, H M Yaish3, E Henry1, L D Eggert1, A M Agarwal2. 1. Women and Newborn's Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA. 2. ARUP Laboratories and the Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. 3. 1] Primary Children's Medical Center, Intermountain Healthcare, Salt Lake City, UT, USA [2] Division of Hematology/Oncology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.
Abstract
OBJECTIVE: We instituted a quality improvement process to enhance our capacity to diagnose genetic hemolytic conditions in neonates with extreme hyperbilirubinemia. STUDY DESIGN: During a 1-year period, whenever the total serum bilirubin (TSB) was >25 mg dl(-1) a special evaluation was performed. If we deemed an erythrocyte membrane defect likely, based on red blood cell morphology, EMA-flow cytometry was performed. Otherwise 'next-generation' sequencing was performed using a panel of genes involved in neonatal hyperbilirubinemia. RESULT: Ten neonates had a TSB ⩾ 25 mg dl(-1). Two others were evaluated as part of this process at the request of their attending neonatologists, because each had a TSB >14 mg dl(-1) in the first hours after birth and required phototherapy for ⩾ 1 week. Explanations for the jaundice were found in all 12 neonates. Five had hereditary spherocytosis, three of which also had ABO hemolytic disease. Two had pyruvate kinase deficiency. One had severe G6PD deficiency. The other four had ABO hemolytic disease. CONCLUSION: On the basis of the present small case series, we suggest that among neonates with extreme hyperbilirubinemia, it can be productive to pursue a genetic basis for hemolytic disease.
OBJECTIVE: We instituted a quality improvement process to enhance our capacity to diagnose genetic hemolytic conditions in neonates with extreme hyperbilirubinemia. STUDY DESIGN: During a 1-year period, whenever the total serum bilirubin (TSB) was >25 mg dl(-1) a special evaluation was performed. If we deemed an erythrocyte membrane defect likely, based on red blood cell morphology, EMA-flow cytometry was performed. Otherwise 'next-generation' sequencing was performed using a panel of genes involved in neonatal hyperbilirubinemia. RESULT: Ten neonates had a TSB ⩾ 25 mg dl(-1). Two others were evaluated as part of this process at the request of their attending neonatologists, because each had a TSB >14 mg dl(-1) in the first hours after birth and required phototherapy for ⩾ 1 week. Explanations for the jaundice were found in all 12 neonates. Five had hereditary spherocytosis, three of which also had ABO hemolytic disease. Two had pyruvate kinase deficiency. One had severe G6PD deficiency. The other four had ABO hemolytic disease. CONCLUSION: On the basis of the present small case series, we suggest that among neonates with extreme hyperbilirubinemia, it can be productive to pursue a genetic basis for hemolytic disease.
Authors: Michael P Mah; Steven L Clark; Efe Akhigbe; Jane Englebright; Donna K Frye; Janet A Meyers; Jonathan B Perlin; Mitch Rodriguez; Arthur Shepard Journal: Pediatrics Date: 2010-04-05 Impact factor: 7.124
Authors: Richard P Wennberg; Charles E Ahlfors; Vinod K Bhutani; Lois H Johnson; Steven M Shapiro Journal: Pediatrics Date: 2006-02 Impact factor: 7.124
Authors: Robert D Christensen; Hassan M Yaish; Susan E Wiedmeier; N Scott Reading; Theodore J Pysher; Cheryl Ann Palmer; Josef T Prchal Journal: Pediatrics Date: 2013-11-11 Impact factor: 7.124
Authors: Robert D Christensen; Hassan M Yaish; Roberto H Nussenzveig; N Scott Reading; Archana M Agarwal; Larry D Eggert; Josef T Prchal Journal: Pediatrics Date: 2013-07-22 Impact factor: 7.124
Authors: Michael Kaplan; Maurizio Muraca; Cathy Hammerman; Firmino F Rubaltelli; Maria T Vilei; Hendrik J Vreman; David K Stevenson Journal: Pediatrics Date: 2002-10 Impact factor: 7.124
Authors: Michael Kaplan; Paul Renbaum; Hendrik J Vreman; Ronald J Wong; Ephrat Levy-Lahad; Cathy Hammerman; David K Stevenson Journal: Pediatr Res Date: 2007-06 Impact factor: 3.756
Authors: Christopher M Richmond; Sally Campbell; Hee W Foo; Sebastian Lunke; Zornitza Stark; Amanda Moody; Elizabeth Bannister; Anthea Greenway; Natasha Brown Journal: Mol Syndromol Date: 2020-02-01
Authors: Paola Bianchi; Elisa Fermo; Bertil Glader; Hitoshi Kanno; Archana Agarwal; Wilma Barcellini; Stefan Eber; James D Hoyer; David J Kuter; Tabita Magalhães Maia; Maria Del Mar Mañu-Pereira; Theodosia A Kalfa; Serge Pissard; José-Carlos Segovia; Eduard van Beers; Patrick G Gallagher; David C Rees; Richard van Wijk Journal: Am J Hematol Date: 2018-11-28 Impact factor: 10.047